

Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology. Among its major competitors, Lexicon Pharmaceuticals is ranked in 9th place for NPS while Seattle Genetics is 1st, and Ultragenyx Pharmaceutical is 2nd. Overall, Lexicon Pharmaceuticals has a neutral social sentiment, when analyzing social media channels and online mentions.Their current market cap is $567.74M